Publications indexed to the term Wet Macular Degeneration
| Faculty | Title |
|---|---|
| 1 | Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy. (Kim JB, Lad EM) Drugs Aging 2021 Jan;38(1):17-27 6 Citations |
| 1 | Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. (Reid CA, Nettesheim ER, Connor TB, Lipinski DM) Sci Rep 2018 Aug 06;8(1):11763 51 Citations |
| 1 | NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators. (Vogel RN, Davis DB, Kimura BH, Rathinavelu S, Graves GS, Szabo A, Han DP) Retina 2017 Feb;37(2):257-264 8 Citations |
| 1 | Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. (Boyer DS, Goldbaum M, Leys AM, Starita C, V.I.S.I.O.N. Study Group) Br J Ophthalmol 2014 Nov;98(11):1543-6 16 Citations |
| 1 | Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. (Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD) JAMA Ophthalmol 2014 Feb;132(2):142-9 353 Citations |
| 1 | Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. (Friberg TR, Tolentino M, LEVEL Study Group, Weber P, Patel S, Campbell S, Goldbaum M) Br J Ophthalmol 2010 Dec;94(12):1611-7 45 Citations |
